MDM2 and cancer: In addition, the C18-CAMEL/p53 plasmid complexes and the MDM2 inhibitor nutlin-3a showed synergistic anticancer activity against the wild-type p53-expressing MCF-7 cells, although this combined therapy was not effective in all tested cancer cell lines.